Pancreatic carcinoma – from current practice to the clinical guidelines

06/2018

Prof. MUDr. Miroslav Ryska, CSc.

Chirurgická klinika 2. LF UK a Ústřední vojenské nemocnice - Vojenské fakultní nemocnice, Praha

SUMMARY

Pancreatic carcinoma is the second most common cancer of the gastrointestinal tract in the Czech Republic after the colorectal cancer and the sixth most common cancer. The 5-year survival rate of all stages of the pancreatic carcinoma is below 5 %. It is expected that in 10-15 years, mortality of pancreatic carcinoma will take the first place among other malignancies. Over the last period, survival has not changed significantly despite the improvement of imaging methods and surgical performance becoming more precise. The pancreatic carcinoma develops relatively slowly, approximately over a decade, and we cure it until its terminal phase. Diseases should be understood as systemic, not local and regional. Improving the quality of guidelines and their compliance is the way to improve the care of these patients at present and in the near future. This is not only a health-organizational problem but also a social and economic problem.

KEY WORDS

pancreatic cancer, diagnosis, therapy, guidelines, AGREE II